EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV …

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV …

In addition to GBM tumor cells being multi-drug resistant, conventional therapies have a difficult time crossing the bloodbrain barrier, and even if this protective barrier is bypassed, the brain is highly sensitive to the broad attack these therapies

(Visited 2 times, 1 visits today)
11
Like
Save

Comments

Comments are disabled for this post.